Medicinova (MNOV) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Medicinova (MNOV) has outperformed PMV Pharmaceuticals (PMVP) over the past year, losing 8.4% versus a loss of 33.6%. Over five years, MNOV leads with a -59.3% price change compared with -96.2% for PMVP. Medicinova is the larger company by market cap ($67.1 million vs $66.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | PMVP |
|---|---|---|
| Share price | $1.31 | $0.876 |
| Market cap | $67.11M | $66.17M |
| 1-day change | +3.15% | -33.13% |
| YTD return | 0.00% | -29.92% |
| 1-year return | -8.39% | -33.64% |
| 5-year return | -59.32% | -96.22% |
| EPS (TTM) | $-0.21 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $409.66K | — |
| Net income (latest FY) | $-12.00M | $-77.74M |
| Operating margin | -3242.47% | — |
| Net margin | -2928.78% | — |
| 52-week high | $3.90 | $1.91 |
| 52-week low | $1.22 | $0.66 |
| Distance from 52-week high | -66.41% | -54.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +529.77% | +356.62% |
| Average volume | 334.96K | 787.50K |
| Shares outstanding | 51.23M | 75.53M |
| Employees | 6 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed PMVP by 25.2 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
MNOV vs PMVP FAQ
Which is bigger, Medicinova or PMV Pharmaceuticals?
Medicinova (MNOV) is larger, with a market capitalization of $67.11M compared with $66.17M for PMV Pharmaceuticals (PMVP).
Which stock has performed better over the past year, MNOV or PMVP?
MNOV returned -8.39% over the past 12 months, compared with -33.64% for PMVP (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.